PDS Biotechnology (PDSB) vs Verrica Pharmaceuticals (VRCA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Verrica Pharmaceuticals (VRCA) over the past year, gaining 2.0% versus a loss of 5.4%. Over five years, PDSB leads with a -91.7% price change compared with -96.9% for VRCA. PDS Biotechnology is the larger company by market cap ($81.5 million vs $71.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PDSB | VRCA |
|---|---|---|
| Share price | $1.13 | $4.16 |
| Market cap | $81.53M | $71.46M |
| 1-day change | +10.29% | -0.48% |
| YTD return | +32.47% | -49.70% |
| 1-year return | +2.00% | -5.43% |
| 5-year return | -91.73% | -96.87% |
| EPS (TTM) | $-0.64 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.55 | $9.82 |
| 52-week low | $0.195 | $3.28 |
| Distance from 52-week high | -27.42% | -57.64% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +344.44% | +232.45% |
| Average volume | 23.24M | 62.56K |
| Shares outstanding | 72.47M | 17.18M |
| Employees | 21 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Verrica Pharmaceuticals
VRCA stock →Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
PDSB vs VRCA FAQ
Which is bigger, PDS Biotechnology or Verrica Pharmaceuticals?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $81.53M compared with $71.46M for Verrica Pharmaceuticals (VRCA).
Which stock has performed better over the past year, PDSB or VRCA?
PDSB returned +2.00% over the past 12 months, compared with -5.43% for VRCA (price return, excluding dividends). Past performance does not predict future results.
Are PDS Biotechnology and Verrica Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.